Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 5Phase 3 2Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 10Rectal Neoplasms 3Stomach Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Colonic Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1Margins of Excision 1Colorectal Cancer Metastatic 1Carcinoma, Neuroendocrine 1

Interventions

Paclitaxel 20Gemcitabine 16Dexamethasone 16Bevacizumab 16Docetaxel 15Oxaliplatin 14Cyclophosphamide 13Carboplatin 12Capecitabine 12Sorafenib 11Fluorouracil 11Leucovorin 10Cisplatin 10pembrolizumab 9Pemetrexed 9Epoetin Alfa 9venetoclax 8Prednisone 8Fentanyl 8Drug Therapy 8Doxorubicin 8atezolizumab 7Rivaroxaban 7Rituximab 7Darbepoetin alfa 7Anastrozole 7Panitumumab 6Ondansetron 6Morphine 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms × IFL protocol × Clear all
NCT00339183 2022-09-23

Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone

Amgen

Phase 3 Completed
1,186 enrolled 18 charts
Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT00115765 2018-10-17

PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study

Amgen

Phase 3 Completed
1,053 enrolled 25 charts
Gastrointestinal

Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡